Profile data is unavailable for this security.
About the company
CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs). All these segments are engaged in the manufacture and sales of related pharmaceutical products. The finished drugs include the antibiotics, cardio-cerebrovascular drugs, diabetes drugs, neurology drugs, oncology drugs and traditional Chinese medicines. The Company is also engaged in the provision of pharmaceutical research and development services, as well as the processing of sewage and pharmaceutical by-products through its subsidiaries.
- Revenue in HKD (TTM)34.01bn
- Net income in HKD6.35bn
- Incorporated1992
- Employees23.50k
- LocationCSPC Pharmaceutical Group LtdNo. 226 Huanghe AvenueSHIJIAZHUANG 050035ChinaCHN
- Phone+86 31 187037015
- Fax+86 31 187039608
- Websitehttps://www.cspc.com.hk/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Akeso Inc | 4.89bn | 2.19bn | 41.95bn | 2.78k | 18.51 | 8.03 | 15.18 | 8.58 | 2.62 | 2.62 | 5.84 | 6.03 | 0.6168 | 0.3671 | 15.98 | 1,760,998.00 | 26.47 | -11.59 | 31.40 | -13.87 | 97.02 | -- | 42.91 | -42.49 | 4.39 | 62,663.10 | 0.3983 | -- | 440.35 | 337.43 | 273.60 | -- | -- | -- |
| Sino Biopharmaceutical Ltd | 28.32bn | 2.00bn | 51.52bn | 25.81k | 22.87 | 1.56 | 8.48 | 1.82 | 0.1198 | 0.148 | 1.52 | 1.75 | 0.4104 | 2.31 | 5.73 | 1,097,294.00 | 7.23 | 13.29 | 13.37 | 22.05 | 80.95 | 79.78 | 17.61 | 27.26 | 0.9649 | 7.33 | 0.2479 | 24.88 | -8.97 | 4.63 | -27.38 | -27.22 | -- | 1.15 |
| WuXi Biologics (Cayman) Inc | 18.41bn | 3.67bn | 54.26bn | 12.74k | 15.26 | 1.24 | 10.13 | 2.95 | 0.835 | 0.835 | 4.23 | 10.24 | 0.321 | 5.04 | 2.85 | 1,445,127.00 | 6.73 | 8.28 | 8.47 | 10.25 | 40.08 | 43.25 | 20.96 | 27.46 | 2.54 | -- | 0.0939 | -- | 11.56 | 46.38 | -23.09 | 40.07 | -- | -- |
| Innovent Biologics Inc | 6.71bn | -1.11bn | 62.55bn | 4.87k | -- | 4.62 | 1,193.96 | 9.33 | -0.7044 | -0.7044 | 4.30 | 8.35 | 0.3248 | 0.9481 | 7.85 | 1,376,771.00 | -5.38 | -13.06 | -6.80 | -15.85 | 81.69 | 84.51 | -16.56 | -43.44 | 2.78 | -- | 0.2242 | -- | 36.21 | 265.79 | 52.83 | -- | -- | -- |
| CSPC Pharmaceutical Group Ltd | 25.79bn | 4.86bn | 77.74bn | 23.50k | 15.95 | 2.16 | 13.19 | 3.01 | 0.4089 | 0.4089 | 2.16 | 3.01 | 0.5421 | 2.48 | 4.79 | 1,097,608.00 | 10.55 | 16.08 | 14.15 | 21.57 | 70.36 | 72.95 | 19.46 | 19.63 | 2.32 | -- | 0.0198 | 35.51 | 1.66 | 12.16 | -3.58 | 13.77 | -- | 25.33 |
| Hansoh Pharmaceutical Group Company Ltd | 10.92bn | 3.54bn | 99.68bn | 9.12k | 28.62 | 3.58 | 25.31 | 9.13 | 0.587 | 0.587 | 1.81 | 4.70 | 0.3206 | 2.01 | 2.99 | 1,197,015.00 | 10.40 | 11.58 | 12.24 | 13.98 | 89.84 | 90.78 | 32.44 | 29.28 | 4.12 | -- | 0.143 | -- | 7.69 | 5.52 | 26.85 | 11.49 | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 05 Apr 2024 | 340.85m | 2.86% |
| First Sentier Investors (Hong Kong) Ltd.as of 31 Dec 2023 | 278.85m | 2.34% |
| First Sentier Investors (UK) IM Ltd.as of 31 Dec 2023 | 191.42m | 1.61% |
| BlackRock Fund Advisorsas of 31 Oct 2023 | 173.68m | 1.46% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 170.52m | 1.43% |
| Hang Seng Investment Management Ltd.as of 03 Apr 2024 | 135.56m | 1.14% |
| UBS Asset Management (Hong Kong) Ltd.as of 12 Apr 2024 | 135.37m | 1.14% |
| UBS Asset Management Switzerland AGas of 12 Apr 2024 | 117.75m | 0.99% |
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 102.49m | 0.86% |
| BlackRock Advisors (UK) Ltd.as of 31 Oct 2023 | 95.02m | 0.80% |
